Search Results
Mar 21, 2026, 07:26 ET Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)
therapyIn addition to improvement in PFS, ZEGFROVY® also showed superior results in all secondary endpoints, including cORR, DOR, DCR, compared to platinum-based chemo doubletZEGFROVY® was generally well tolerated with a safety profile
More news about: Dizal
Mar 17, 2026, 16:35 ET Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (
More news about: Nuvation Bio Inc.
Mar 02, 2026, 16:05 ET Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (
More news about: Nuvation Bio Inc.
Mar 02, 2026, 07:43 ET Consortium Led by Global Infrastructure Partners and EQT Agrees to Acquire AES
platform, including enhancing reliability and long-term competitiveness, while supporting a responsible and sustainable energy transition."Sarah Corr, Managing Investment Director for Real Assets for CalPERS, said, "We are pleased to participate in this landmark investment in AES. The Company's
More news about: EQT
Mar 02, 2026, 07:38 ET Consortium Led by Global Infrastructure Partners and EQT Agrees to Acquire AES
platform, including enhancing reliability and long-term competitiveness, while supporting a responsible and sustainable energy transition."Sarah Corr, Managing Investment Director for Real Assets for CalPERS, said, "We are pleased to participate in this landmark investment in AES. The Company's
More news about: EQT
Mar 02, 2026, 07:00 ET Consortium Led by Global Infrastructure Partners and EQT Agrees to Acquire AES
platform, including enhancing reliability and long-term competitiveness, while supporting a responsible and sustainable energy transition."Sarah Corr, Managing Investment Director for Real Assets for CalPERS, said, "We are pleased to participate in this landmark investment in AES. The Company's
More news about: The AES Corporation
Feb 12, 2026, 19:00 ET Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
was 4) and were treated with 6-15 mg/kg doses of IBI354.As of March 24, 2025, the overall confirmed objective response rate (cORR) was 59.1% and the disease control rate (DCR) was 90.9%.Among them, ORR reached 72.4% and DCR reached 89.7% in 29 breast cancer participants
More news about: Innovent Biologics
Jan 05, 2026, 16:59 ET Hood College Receives Grant from Delaplaine Foundation Inc. to Expand Local Youth Literacy Programs
together three of our grantees, Hood College, the Boys & Girls Club of Frederick County, and the Housing Authority of Frederick City," said Michele Corr, executive director for Delaplaine Foundation Inc. "This program will develop the expertise and confidence of future reading specialists through
More news about: Hood College
Nov 03, 2025, 01:07 ET StarCompliance Study Finds UAE Firms Making Training and Competency Top Priorities
how quickly the regulatory landscape is evolving and how seriously firms in the region are investing in people, process, and technology," said Callum Corr, Associate Director, StarCompliance. "Star remains at the forefront of partnering with firms worldwide, delivering innovation that advances regulatory
More news about: StarCompliance
Oct 24, 2025, 04:40 ET Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website
gemcitabine-containing monotherapy chemotherapy regimen! The confirmed Objective Response Rate (cORR) reached 54.6%, significantly higher than 27.0% in the control group, achieving a doubling; subgroup analysis showed that regardless of patient baseline
More news about: eChinaHealth
Oct 22, 2025, 04:00 ET Jacobs Selected to Design UK's Uxbridge Moor Substation
the new 132kV substation will be via 132kV underground cables. Murphy Managing Director of Energy Liam Corr said: "Since 1951 Murphy has been a leading provider of innovative and integrated energy solutions – today we support groundbreaking energy transmission
More news about: Jacobs